These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9153413)

  • 21. Osteopontin enhances phagocytosis through a novel osteopontin receptor, the alphaXbeta2 integrin.
    Schack L; Stapulionis R; Christensen B; Kofod-Olsen E; Skov Sørensen UB; Vorup-Jensen T; Sørensen ES; Höllsberg P
    J Immunol; 2009 Jun; 182(11):6943-50. PubMed ID: 19454691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.
    Zhu Y; Denhardt DT; Cao H; Sutphin PD; Koong AC; Giaccia AJ; Le QT
    Oncogene; 2005 Sep; 24(43):6555-63. PubMed ID: 16007184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways.
    Tuck AB; Hota C; Wilson SM; Chambers AF
    Oncogene; 2003 Feb; 22(8):1198-205. PubMed ID: 12606946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.
    Castellone MD; Celetti A; Guarino V; Cirafici AM; Basolo F; Giannini R; Medico E; Kruhoffer M; Orntoft TF; Curcio F; Fusco A; Melillo RM; Santoro M
    Oncogene; 2004 Mar; 23(12):2188-96. PubMed ID: 14981541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin.
    Furger KA; Allan AL; Wilson SM; Hota C; Vantyghem SA; Postenka CO; Al-Katib W; Chambers AF; Tuck AB
    Mol Cancer Res; 2003 Sep; 1(11):810-9. PubMed ID: 14517343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expression and localization of surface neoantigens in transformed and untransformed cultured cells infected with avian tumor viruses.
    Phillips ER; Perdue JF
    J Supramol Struct; 1976; 4(1):27-44. PubMed ID: 1256061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure and membrane topology of the high-affinity receptor for human IFN-gamma: requirements for binding IFN-gamma. One single 90-kilodalton IFN-gamma receptor can lead to multiple cross-linked products and isolated proteins.
    Fountoulakis M; Kania M; Ozmen L; Loetscher HR; Garotta G; van Loon AP
    J Immunol; 1989 Nov; 143(10):3266-76. PubMed ID: 2530276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coordinate expression of OPN and associated receptors during monocyte/macrophage differentiation of HL-60 cells.
    Atkins K; Berry JE; Zhang WZ; Harris JF; Chambers AF; Simpson RU; Somerman MJ
    J Cell Physiol; 1998 May; 175(2):229-37. PubMed ID: 9525482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
    Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
    Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration.
    Zohar R; Suzuki N; Suzuki K; Arora P; Glogauer M; McCulloch CA; Sodek J
    J Cell Physiol; 2000 Jul; 184(1):118-30. PubMed ID: 10825241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced expression of alpha v integrin subunit and osteopontin during differentiation of HL-60 cells along the monocytic pathway.
    Somerman MJ; Berry JE; Khalkhali-Ellis Z; Osdoby P; Simpson RU
    Exp Cell Res; 1995 Feb; 216(2):335-41. PubMed ID: 7843278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts.
    Petrow PK; Hummel KM; Schedel J; Franz JK; Klein CL; Müller-Ladner U; Kriegsmann J; Chang PL; Prince CW; Gay RE; Gay S
    Arthritis Rheum; 2000 Jul; 43(7):1597-605. PubMed ID: 10902765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice.
    Bourassa B; Monaghan S; Rittling SR
    Cell Immunol; 2004 Jan; 227(1):1-11. PubMed ID: 15051510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osteopontin: possible role in prostate cancer progression.
    Thalmann GN; Sikes RA; Devoll RE; Kiefer JA; Markwalder R; Klima I; Farach-Carson CM; Studer UE; Chung LW
    Clin Cancer Res; 1999 Aug; 5(8):2271-7. PubMed ID: 10473115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions.
    Wang D; Yamamoto S; Hijiya N; Benveniste EN; Gladson CL
    Oncogene; 2000 Nov; 19(50):5801-9. PubMed ID: 11126367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor.
    Schultz J; Lorenz P; Ibrahim SM; Kundt G; Gross G; Kunz M
    Mol Carcinog; 2009 Jan; 48(1):14-23. PubMed ID: 18459127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of anti-osteopontin monoclonal antibodies: Binding sensitivity to post-translational modifications.
    Kazanecki CC; Kowalski AJ; Ding T; Rittling SR; Denhardt DT
    J Cell Biochem; 2007 Nov; 102(4):925-35. PubMed ID: 17786932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temperature sensitive phosphoproteins in rat cells transformed by a temperature sensitive mutant of rous sarcoma virus.
    Segawa K; Kawai S
    J Biochem; 1980 Jul; 88(1):277-80. PubMed ID: 6251036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transforming growth factor production by chemically transformed cells.
    Moses HL; Branum EL; Proper JA; Robinson RA
    Cancer Res; 1981 Jul; 41(7):2842-8. PubMed ID: 6265069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in both glycosylation and binding properties between rat and mouse liver prolactin receptors.
    Lascols O; Cherqui G; Munier A; Picard J; Capeau J
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):359-71. PubMed ID: 7920180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.